Brexpiprazole for agitation in clinically relevant patient subgroups: a <i>post hoc</i> analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer’s disease
In these exploratory analyses, brexpiprazole reduced symptoms of agitation across a wide range of patients with agitation associated with dementia due to Alzheimer's disease.
Authors
- George T. Grossberg (ORCID: https://orcid.org/0000-0002-1493-3931)
- Malaak Brubaker
- Sanjeda R Chumki
- Pedro Such (ORCID: https://orcid.org/0000-0003-1905-1142)
- Jeffrey L. Cummings (ORCID: https://orcid.org/0000-0001-8944-4158)
- Zhen Zhang (ORCID: https://orcid.org/0000-0002-6512-1458)
- Anton M. Palma (ORCID: https://orcid.org/0000-0003-1009-4701)
- David Wang (ORCID: https://orcid.org/0000-0003-2277-4608)
- Jared Stroud
Institutions
- Lundbeck (Denmark) (DK)
- University of Nevada, Las Vegas (US)
- The Ohio State University Wexner Medical Center (US)
- Otsuka (United States) (US)
- Deerfield (United States) (US)
- UCLouvain Saint-Louis Brussels (BE)
- Otsuka Pharmaceutical (Spain) (ES)
- Lundbeck (United States) (US)
- Saint Louis University (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1080/03007995.2025.2552278
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26
Funders
- H. Lundbeck A/S
- Otsuka Pharmaceutical Development and Commercialization